Enhabit Announces Participation in Upcoming Goldman Sachs 45th Annual Global Healthcare Conference
Enhabit, Inc. (NYSE:EHAB), a leading national home health and hospice provider, today announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. Enhabit's President and Chief Executive
Enhabit Announces Participation in Upcoming Leerink Partners Healthcare Crossroads Conference 2024
Enhabit, Inc. (NYSE:EHAB), a leading national home health and hospice provider, today announced its participation in the Leerink Partners Healthcare Crossroads Conference 2024. Enhabit's President and Chief Executive
Enhabit(EHAB.US) Director Buys US$83,300 in Common Stock
$Enhabit(EHAB.US)$ Director Bolton Jeffrey purchased 10,000 shares of common stock on May 17, 2024 at an average price of $8.33 for a total value of $83,300.Source: Announcement What is statement of c
Enhabit(EHAB.US) Director Buys US$18,000 in Common Stock
$Enhabit(EHAB.US)$ Director Hoeflinger Erin purchased 2,000 shares of common stock on May 14, 2024 at an average price of $9 for a total value of $18,000.Source: Announcement What is statement of chan
Analyst Expectations For Enhabit's Future
Throughout the last three months, 5 analysts have evaluated Enhabit (NYSE:EHAB), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings, sheddin
Enhabit Raised to Market Perform From Underperform by Leerink Partners
Enhabit Raised to Market Perform From Underperform by Leerink Partners
Enhabit Price Target Announced at $8.50/Share by Leerink Partners
Enhabit Price Target Announced at $8.50/Share by Leerink Partners
Leerink Partners: Upgraded the Enhabit (EHAB.US) rating from lower than the market to a consistent market rating, with a target price of $8.50.
Leerink Partners: Upgraded the Enhabit (EHAB.US) rating from lower than the market to a consistent market rating, with a target price of $8.50.
Leerink Partners Upgrades Enhabit to Market Perform From Underperform, Price Target Is $8.50
Enhabit (EHAB) has an average rating of hold and price targets ranging from $8.50 to $12, according to analysts polled by Capital IQ.
Hold Rating on Enhabit, Inc. Maintained Amid EBITDA Beat and Ongoing Uncertainties
Enhabit(EHAB.US) Director Buys US$82,400 in Common Stock
$Enhabit(EHAB.US)$ Director Bolton Jeffrey purchased 10,000 shares of common stock on May 10, 2024 at an average price of $8.24 for a total value of $82,400.Source: Announcement What is statement of c
Enhabit Inc (EHAB) Reports Mixed Q1 2024 Results: Challenges and Strategic Adjustments Highlighted
UBS Trims Price Target on Enhabit to $9 From $10, Keeps Neutral Rating
Enhabit (EHAB) has an average rating of hold and price targets ranging from $8.50 to $12, according to analysts polled by Capital IQ. Price: 8.04, Change: -0.25, Percent Change: -3.08
Enhabit (NYSE:EHAB) Will Be Looking To Turn Around Its Returns
If we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? Businesses in decline often have two underlying trends, firstly, a declining return on cap
Leerink Partners Sticks to Its Sell Rating for Enhabit, Inc (EHAB)
Enhabit | 10-Q: Quarterly report
Enhabit Cut to Hold From Buy by Jefferies
Enhabit Cut to Hold From Buy by Jefferies
Jefferies Downgrades Enhabit to Hold, Lowers Price Target to $8.75
Jefferies analyst Brian Tanquilut downgrades Enhabit from Buy to Hold and lowers the price target from $14 to $8.75.
Enhabit Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 5.29% Jefferies $14 → $8.75 Downgrades Buy → Hold 03/11/2024 32.37% TD Cowen $12 → $11 Maintain
AREX Capital Expresses Disappointment In Enhabit's Strategic Review Conclusion; Believes Enhabit's Shares Do Not Reflect Its Intrinsic Value Or Strategic Potential
Believes Enhabit's Shares Do Not Reflect its Intrinsic Value or Strategic PotentialHas Nominated Seven Highly Qualified Independent DirectorsBelieves AREX Slate Would Provide Board With Sorely Needed